Cancer ScreeningProstate Cancer

PSA Screening Saved His Life, Said Ben Stiller After Being Diagnosed with Prostate Cancer

You know Ben Stiller as the comedic actor who made you laugh in “There’s Something About Mary,” “Zoolander,” and “Meet the Parents,” but this legend of the silver screen credits a PSA screening for saving his life.
August 2017 Vol 3 No 4
Maurie Markman, MD
President of Medicine & Science
Cancer Treatment Centers of America

In an article he posted online in October 2016, the actor Ben Stiller revealed that he was diagnosed with prostate cancer in 2014.1 He described the positive effects of undergoing prostate-specific antigen (PSA) screening for prostate cancer and discussed the current controversy among experts who debate whether PSA screening is a good idea.

The PSA Screening Controversy

The PSA test measures the levels of a chemical specific to the prostate gland in men. Elevated PSA levels in the blood may indicate that the man has prostate cancer, but high PSA levels can also suggest other potential problems not always related to cancer.

Because of its low level of specificity (that is, inability to zero in on one reason), the PSA test does not differentiate between lethal and nonlethal types of cancer, or even between other medical conditions—such as benign prostatic hyperplasia (or BPH) or early prostate cancer—that are either not related to cancer or show a tumor that is very slow-growing and most likely will not be life-threatening and should not be treated.

This explains why using PSA screening to detect prostate cancer has been associated with too many (and sometimes false) diagnoses of prostate cancer, which can result in overtreatment in men who may not need treatment. This has caused some experts to suggest that PSA screenings may not be a good way to diagnose prostate cancer.

Ben Stiller’s Case

In Stiller’s case, his doctor recommended that he undergo a baseline PSA test at age 46, even though he had no symptoms and had no known risk for this cancer.

“Taking the PSA test saved my life. Literally. That’s why I am writing this now. There has been a lot of controversy over the test in the last few years,”1 Stiller writes. During the next year and a half, his PSA level kept rising, so eventually, his urologist performed a physical exam to determine why.

Based on the physical exam, the urologist ordered an MRI test and then a biopsy, which, to his surprise, showed a Gleason score of 7. A Gleason score helps predict the aggressiveness of prostate cancer. Stiller’s score indicated “mid-range aggressive cancer.”

Stiller was told that the disease was detected early and was treatable. He opted to remove the tumor with a robotic-assisted laparoscopic radical prostatectomy, and no sign of cancer was detectable after that treatment.

Stiller wrote in his blog, “I got diagnosed with prostate cancer Friday, June 13th, 2014. On September 17th of that year, I got a test back telling me I was cancer free. The three months in between were a crazy roller coaster ride with which about 180,000 men a year in America can identify.”1

Second Most Common Cancer in Men, but Experts Disagree about Testing

Prostate cancer is the second most common cancer in men in the United States, after skin cancer; 1 in 7 men in the United States will be diagnosed with this type of cancer in their lifetime. The medical community is not in agreement about whether, or at what age, men should be screened for prostate cancer; instead, men are urged to talk to their doctors about whether and when they should be tested for this disease.

The American Cancer Society and the American Urological Association recommend that PSA testing should begin at age 40 for men who are at high risk; in addition, the American Cancer Society suggests that all men who are not at high risk should begin PSA testing at age 50.

Those who are considered to be at high risk for prostate cancer are African American men and men whose father, brother, or son was diagnosed with prostate cancer at an early age.

“This is a complicated issue, and an evolving one,” Stiller writes. “But in this imperfect world, I believe the best way to determine a course of action for the most treatable, yet deadly cancer, is to detect it early.”1

Advocate for PSA Screening

Because prostate cancer typically has no warning signs or symptoms until it has progressed to the advanced stages, screening may help catch it before it spreads, and when it can still be successfully treated. That was the case for Stiller, who credits his doctor for being proactive.

“If he had waited, as the American Cancer Society recommends until I was 50, I would not have known I had a growing tumor until two years after I got treated,” Stiller writes. “If he had followed the U.S. Preventive Services Task Force guideline, I would have never gotten tested at all, and not have known I had cancer until it was way too late to treat successfully.”1

The Stiller Effect?

Some people have suggested that his disclosure could lead to a so-called Stiller effect on early screenings for prostate cancer, similar to the impact that the actress Angelina Jolie had on genetic testing for breast cancer associated with the BRCA genetic mutation, or the spike in colonoscopies that was attributed to Katie Couric after she had a colonoscopy performed live on the Today Show following her husband’s death from colon cancer in 1998.

But Sean Cavanaugh, MD, Chief of Radiation Oncology at the Cancer Treatment Centers of America near Atlanta, is doubtful. “Sadly, I don’t see this being similar to those examples,” Dr. Cavanaugh says. “Colonoscopy and BRCA testing were recommended screenings that celebrities pushed into the spotlight. Stiller is pushing something that isn’t part of current national guidelines—his viewpoint is deeply opposed by the powers that be. While I wish his story would move the needle on PSA screening, I would be surprised,” he noted.

However, even if Stiller’s disclosure only sparks a conversation between men and their doctors about the optimal time to begin prostate cancer screenings, many people may consider that a success and a contribution to men’s health.


  1. Stiller B. The prostate cancer test that saved my life. October 4, 2016.

This article is based, in part, on a blog prepared by Cancer Treatment Centers of America, with clinical oversight by Maurie Markman, MD.

Key Points

  • Prostate cancer is the second most common cancer in men in the United States, after skin cancer
  • 1 in 7 men in the United States will be diagnosed with this type of cancer in their lifetime
  • The American Cancer Society and the American Urological Association recommend PSA testing at age 40 for men at high risk and at age 50 for other men
  • African American men, and men whose father, brother, or son was diagnosed with prostate cancer at an early age are at high risk for prostate cancer
  • Because this cancer typically has no warning signs until it has progressed to the advanced stages, screening may help to catch it early when it can still be cured

Share this:

Recommended For You
Prostate Cancer
Drugs for Prostate Cancer
Here are the drugs and financial support services available to patients receiving treatment for Prostate Cancer.
Breast CancerCancer ScreeningSurvivorship
Get Those Mammograms as Prescribed!
By Ginger Modiri
Breast cancer survivor Ginger Modiri stresses the importance of getting mammograms on time. To celebrate her 8-year anniversary of being cancer-free she organized a walk after the More than Pink Walk was cancelled because of COVID-19.
Prostate Cancer
Lynparza Improves Quality of Life in Men with Metastatic Prostate Cancer
By Meg Barbor, MPH
The PARP inhibitor Lynparza (olaparib), a type of drug that is usually used for the treatment of women with ovarian cancer, has also been studied in men with prostate cancer. The results of the PROfound clinical trial were recently presented at the 2020 ASCO annual meeting by Antoine Thiery-Vuillemin, MD, PhD, Centre Hospitalier de Besançon, France.
Prostate Cancer
The Combination of Cabometyx plus Tecentriq Improves Outcomes in Patients with Advanced Prostate Cancer
By Meg Barbor, MPH
Results of a new study showed that the combination of Cabometyx (cabozantinib) and the immune checkpoint inhibitor Tecentriq (atezolizumab) was safe and effective in men with metastatic (spreading) castration-resistant prostate cancer, the most common type of prostate cancer.
Last modified: June 23, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.